Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
What is your experience of using rituximab for GPA with renal involvement following a recent myocardial infarction?
Related Questions
How would you approach a patient with EGPA, with main manifestations of asthma, nasal polyposis, and mononeuritis multiplex, who has clinically responded to rituximab, yet has persistently high eosinophilia (>40%)?
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?
How long do you continue rituximab in patients with ANCA associated vasculitis who have achieved remission?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
Do you consider immunosuppression in a patient with cocaine-induced midline lesions who is ANCA positive, but has no other evidence of vasculitis?
How would you approach a male in his 60s with bilateral optic perineuritis/neuritis on MRI, steroid-responsive bilateral jaw pain, normal ESR/CRP, negative temporal artery biopsy, and elevated IgG4?
Would you consider switching to benralizumab for patients with EGPA experiencing severe pulmonary symptoms despite being on mepolizumab?
How would you interpret the presence of both high titer anti-PR3 and anti-MPO antibodies in a pANCA positive patient with evidence of small vessel vasculitis?
How would you approach the evaluation and management of isolated vasculitis with aneurysms involving the segmental hepatic arteries causing hepatic hemorrhage in an otherwise healthy patient in his 80s?
